Table 1. Baseline Characteristics.
Participants with both eyes enrolled are counted twice (by eye), once for each of the treatment sequences to which an eye was randomly assigned.
| Variable | Category | RRB | RBB | BBR | BRR | Total |
|---|---|---|---|---|---|---|
| Group | Total Eyes | 17 | 15* | 16 | 14 | 62 |
| Age (years) | Min / Median (Mean) / Max | 39 / 61 (62.4) /85 | 39 / 66 (65.9) /87 | 39 / 63 (62.3) /83 | 51 / 61.5 (61.8) /82 | 39 / 62 (63) /87 |
| Diabetes Type | Type 1 | 2 (11.8%) | 2 (13.3%) | 1 (6.3%) | 2 (14.3%) | 7 (11.3%) |
| Type 2 | 15 (88.2%) | 13 (86.7%) | 15 (93.8%) | 12 (85.7%) | 55 (88.7%) | |
| Hemoglobin | Min / Median (Mean) / Max | 6.2 / 7.4 (8.1) / 11.5 | 5.8 / 7.8 (8.4) / 12.2 | 6.2 / 7.9 (7.9) / 10.6 | 5.8 / 7.6 (7.8) / 10.3 | 5.8 / 7.6 (8.1) / 12.2 |
| A1C (%) | ≥ 8.0% | 6 (35%) | 6 (40%) | 7 (43%) | 5 (35%) | 24 (38%) |
| Gender | Female | 4 (23.5%) | 8 (53.3%) | 7 (43.8%) | 5 (35.7%) | 24 (38.7%) |
| Male | 13 (76.5%) | 7 (46.7%) | 9 (56.3%) | 9 (64.3%) | 38 (61.3%) | |
| Race | Asian | 1 (5.9%) | 0 (0%) | 1 (6.3%) | 1 (7.1%) | 3 (4.8%) |
| (Participant-reported) | Black | 2 (11.8%) | 2 (13.3%) | 2 (12.5%) | 2 (14.3%) | 8 (12.9%) |
| Multiple race | 1 (5.9%) | 0 (0%) | 2 (12.5%) | 0 (0%) | 3 (4.8%) | |
| Unknown | 1 (5.9%) | 0 (0%) | 0 (0%) | 1 (7.1%) | 2 (3.2%) | |
| White | 12 (70.6%) | 13 (86.7%) | 11 (68.8%) | 10 (71.4%) | 46 (74.2%) | |
| Ethnicity | Unknown | 0 (0%) | 0 (0%) | 1 (6.3%) | 0 (0%) | 1 (1.6%) |
| (Participant-reported) | Hispanic or Latino | 2 (11.8%) | 0 (0%) | 1 (6.3%) | 0 (0%) | 3 (4.8%) |
| Not Hispanic or Latino | 15 (88.2%) | 15 (100%) | 14 (87.5%) | 14 (100%) | 58 (93.5%) | |
| Best-Corrected Visual Acuity (letters) | Min / Median (Mean) / Max | 38 / 69 (65) / 78 | 32 / 64 (61) / 73 | 44 / 69 (65) / 75 | 50 / 64 (65) / 78 | 32 / 66 (64) / 78 |
| OCT Central Subfield Mean Thickness (μm) | Min / Median (Mean) / Max | 334 / 496 (484) / 720 | 366 / 435 (444) / 602 | 362 / 432 (471) / 606 | 358 / 508 (508) / 653 | 334 / 453 (477) / 720 |
*
One participant with a single eye assigned to the RBB group withdrew after the week 4 visit following a cerebrovascular accident and was not included in the analysis; all other participants/eyes completed the study and were included in the analysis.